PDCD1 and melanoma: Six patients had ICI therapy with a PD-1 inhibitor as first-line therapy, while two patients (melanoma) received combined ICI therapy with PD-1 plus CTLA-4 inhibitors (patient #1, 3); both of them showed a complete remission (CR) of the melanoma.